[
  {
    "ts": null,
    "headline": "EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes",
    "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
    "url": "https://finnhub.io/api/news?id=8c4bdb9db29c78d4a11052a2b2b96e252e44d200bcf426dfa45700c7ba880a35",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745509140,
      "headline": "EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes",
      "id": 134067483,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.",
      "url": "https://finnhub.io/api/news?id=8c4bdb9db29c78d4a11052a2b2b96e252e44d200bcf426dfa45700c7ba880a35"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction",
    "summary": "Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=8e24d070581b2c4435c3ded52e3894495a6f5d2e65d4c54b9d5afe03dfcaaa6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745500920,
      "headline": "The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction",
      "id": 134067460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=8e24d070581b2c4435c3ded52e3894495a6f5d2e65d4c54b9d5afe03dfcaaa6f"
    }
  },
  {
    "ts": null,
    "headline": "Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)",
    "summary": "Key Insights Abbott Laboratories' estimated fair value is US$132 based on 2 Stage Free Cash Flow to Equity Current...",
    "url": "https://finnhub.io/api/news?id=2287ee957b376592cfed06f73ee1565faad7bda6a7d47e15608cec920fefb530",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745492415,
      "headline": "Calculating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)",
      "id": 134059332,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Key Insights Abbott Laboratories' estimated fair value is US$132 based on 2 Stage Free Cash Flow to Equity Current...",
      "url": "https://finnhub.io/api/news?id=2287ee957b376592cfed06f73ee1565faad7bda6a7d47e15608cec920fefb530"
    }
  }
]